Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Akane Takami"'
Autor:
Robert Spranger, Elisabeth Niemoeller, Atsushi Amano, Akane Takami, Daisuke Watanabe, Hideaki Kaneto
Publikováno v:
Diabetes, Obesity and Metabolism. 22:3-13
AIMS To assess efficacy and safety of fixed-ratio (1:1) combination insulin glargine and lixisenatide (iGlarLixi) compared to insulin glargine U100 (iGlar), with metformin, in Japanese patients with type 2 diabetes mellitus (T2DM) inadequately contro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9070a2a25db8854d47599bd0851cc3c
https://doi.org/10.1111/dom.14005
https://doi.org/10.1111/dom.14005
Autor:
Atsushi Amano, Hirotaka Watada, Robert Spranger, Elisabeth Niemoeller, Akane Takami, Yasuhiro Hashimoto
Publikováno v:
Diabetes Care
OBJECTIVE To assess the efficacy and safety of a 1:1 fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) versus lixisenatide (Lixi) in insulin-naive Japanese patients with type 2 diabetes mellitus (T2DM) inadequately controlled o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9fd0bf5d1cbb7ea92dd5fd11872adde7
http://europepmc.org/articles/PMC7245357
http://europepmc.org/articles/PMC7245357
Autor:
Elisabeth Niemoeller, Yasuhiro Hashimoto, Atsushi Amano, Robert Spranger, Akane Takami, Hirotaka Watada
OBJECTIVE: To assess the efficacy and safety of a 1:1 fixed ratio combination of insulin glargine and lixisenatide (iGlarLixi) versus lixisenatide (Lixi) in insulin-naïve Japanese patients with type 2 diabetes mellitus inadequately controlled on ora
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::349ec64626cc72c2fb46ae240ac2f7d9
https://doi.org/10.2337/dc20-1234/suppl.12016425
https://doi.org/10.2337/dc20-1234/suppl.12016425
Autor:
Hirotaka Watada, Akane Takami, Spranger, Robert, Atsushi Amano, Yasuhiro Hashimoto, Niemoeller, Elisabeth, Watada, Hirotaka, Takami, Akane, Amano, Atsushi, Hashimoto, Yasuhiro
Publikováno v:
Diabetes Care; Jun2020, Vol. 43 Issue 6, p1249-1257, 9p
Publikováno v:
Journal of Diabetes Investigation
Aim/Introduction To assess the overall safety and efficacy of lixisenatide in combination with background oral antidiabetic drug treatment in Japanese patients with type 2 diabetes, as required by Japanese guidelines. Materials and Methods A phase 3,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33e1c273bee6924474c84a24cdd45bc0
https://doi.org/10.1111/jdi.12686
https://doi.org/10.1111/jdi.12686
Autor:
Hideaki Kaneto, Akane Takami, Robert Spranger, Atsushi Amano, Elisabeth Niemoeller, Daisuke Watanabe
Publikováno v:
Diabetes. 68
The fixed ratio combination of insulin glargine/lixisenatide (iGlarLixi) has been shown in a Western population to improve glycemic control in a convenient single daily injection. This open-label trial assessed the efficacy and safety of 26-week trea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1dbf53bf67e2a70e4bb66ceaa46bab08
https://doi.org/10.2337/db19-1032-p
https://doi.org/10.2337/db19-1032-p
Autor:
Richard M. Bergenstal, Jeffrey Unger, Elisabeth Niemoeller, Carol Wysham, Hailing Guo, Guillermo González-Gálvez, Elisabeth Souhami, Diego Bellido, Akane Takami, Julio Rosenstock, Vanita R. Aroda
Publikováno v:
Diabetes Care. 39:1972-1980
OBJECTIVE This study was conducted to demonstrate the efficacy and safety of LixiLan (iGlarLixi), a novel, titratable, fixed-ratio combination of insulin glargine (iGlar) (100 units) and lixisenatide, compared with iGlar in patients with type 2 diabe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::54bd2d4311a42b228cd5e11c50c78898
https://doi.org/10.2337/dc16-1495
https://doi.org/10.2337/dc16-1495
Autor:
Hailing Guo, Diego Bellido, Vanita R. Aroda, Elisabeth Niemoeller, Elisabeth Souhami, Jeffrey Unger, Akane Takami, Richard M. Bergenstal, Carol Wysham, Julio Rosenstock, Guillermo González-Gálvez
Publikováno v:
Diabetes Care
This study was conducted to demonstrate the efficacy and safety of LixiLan (iGlarLixi), a novel, titratable, fixed-ratio combination of insulin glargine (iGlar) (100 units) and lixisenatide, compared with iGlar in patients with type 2 diabetes inadeq
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb30e599940886b504bf8cccad47d704
https://pubmed.ncbi.nlm.nih.gov/27650977
https://pubmed.ncbi.nlm.nih.gov/27650977
Publikováno v:
Journal of Diabetes and its Complications. (8):1304-1309
Aims This 76-week, open-label, parallel-group study assessed the long-term safety of once-daily lixisenatide monotherapy in Japanese patients with type 2 diabetes mellitus. Methods Patients were randomized to receive lixisenatide in a 2-step or a 1-s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b955b4089681ce35f9bfa774686ba373
Publikováno v:
In Journal of Diabetes and Its Complications November-December 2015 29(8):1304-1309